Palatin Technologies develops biopharmaceutical product candidates based on molecules that modulate the melanocortin receptor system. Company news centers on its melanocortin-based obesity programs, including oral small-molecule and peptide MC4R agonists, with focus areas that include hypothalamic obesity and Prader-Willi syndrome.
Recurring updates also cover ocular and retinal disease assets, including PL9643 for dry eye disease and PL9654 and PL9655 for diabetic retinopathy, along with research collaborations, sublicensing agreements, public offerings, reverse-stock-split actions, exchange trading status and financial results.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Palatin Technologies presented promising data on its Phase 3 clinical trial for PL9643, a treatment for dry eye disease (DED), at the ARVO Annual Conference. The data shows consistent efficacy across multiple signs and symptoms of DED, demonstrating PL9643's potential as a leading treatment option. The ongoing MELODY-1 clinical study aims to finalize data in the second half of 2023, highlighting the significant differences in effectiveness compared to existing therapies. Notably, PL9643 showed no ocular adverse events, illustrating its strong safety and tolerability profile. The findings reinforce PL9643's potential to address unmet needs in DED patients, with over 20 million affected in the U.S.
Palatin Technologies (NYSE American: PTN) presented a poster at the ARVO Annual Conference showcasing their research on PL9588, a novel treatment aimed at reducing intraocular pressure (IOP) for glaucoma patients. The study demonstrated that PL9588 effectively lowered IOP in normotensive rabbits, showcasing effects comparable to established treatments like latanoprost and timolol. The results indicate that the treatment could persist for 24 hours and may offer neuroprotective benefits. The global glaucoma market, valued at $5.71 billion in 2021, is expected to reach $9.77 billion by 2030, signaling significant potential for new treatments. Palatin plans to advance PL9588 into clinical development, subject to resources. This innovative approach may significantly improve patient outcomes and enhance treatment options for glaucoma.
Palatin Technologies, Inc. (NYSE American: PTN) reported preliminary revenue results for its product Vyleesi for the fiscal third quarter ending March 31, 2023. The company achieved $3.4 million in gross product revenue, marking a 31% increase from the previous quarter and 165% growth year-over-year. Net product revenue reached $1.2 million, representing a 22% increase over 2Q23 and 469% growth compared to 3Q22. The total prescriptions dispensed grew by 27% over the prior quarter and 147% year-over-year. Palatin's focus on targeted digital marketing is credited for this growth, with net product revenue exceeding the operating expenses of Vyleesi.
Palatin Technologies (NYSE American: PTN) announced the publication of a manuscript in the International Journal of Molecular Sciences, highlighting PL8331’s therapeutic effects in diabetic retinopathy and uveitis. The study, funded by Palatin and NIH, demonstrated PL8331's efficacy as a melanocortin agonist in mouse models, showing promise in reducing inflammation and preserving retinal structure. Notably, in the EAU model, PL8331 protected retinal cells from damage, while in the DR model, it enhanced cell survival and suppressed VEGF, crucial in DR pathology. The findings underscore the potential of melanocortin agonists in treating inflammatory eye diseases and support future clinical development for Palatin. CEO Carl Spana emphasized the growing pre-clinical data supporting these prospects.
Palatin Technologies, Inc. (NYSE American: PTN) announced a study published in Frontiers in Immunology, highlighting the therapeutic effects of its oral formulation, PL8177, in preclinical models of inflammatory bowel disease. The study reports that PL8177 remains gut-restricted, showing promising results such as reduced immune cell infiltration and improved colon structure. Pharmacokinetic studies indicated that PL8177 is effective in the colon without systemic absorption. The company is currently enrolling patients in a Phase 2 clinical trial for ulcerative colitis. Initial results from the trial are expected in mid-2023, with final data anticipated later in the year.